sprite-preloader
Anzeige
Mehr »
Mittwoch, 12.12.2018 Börsentäglich über 12.000 News von 600 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

Aktuelle News von Endpoints News

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
13:35FDA rolls out expectations for a looming regulatory shift for insulin and other biologics
12:35Eli Lilly is going for it again, inking $2B Alzheimer's deal for tau therapies with AC Immune
DiAmgen enlists Entera in a drug discovery pact; Boehringer brings out the budget ax
DiLarge coalition joins drug lobby in denouncing Trump proposal to import drug prices for Medicare
DiClive Meanwell gives way to new CEO as activist investor Alex Denner shakes up The Medicines Company
DiFreshman lawmakers give J&J CEO Alex Gorsky another unwanted turn in the public spotlight
DiBlack Diamond turns down an open stretch of R&D highway, headed to a showdown with oncogenes
DiAnti-CD47 gel could stem tumors from resurfacing, study in mice suggests
DiToo much success? A booming biotech pipeline will spur intense rivalries - analyst
DiSue Dillon, Karyn O'Neil steer fledgling Aro Biotherapeutics to $13M debut -- with J&J's blessing
DiIonis is focused on treating the untreatable with medical breakthroughs for patients
MoShanghai Junshi Biosciences next to test HKEX listing; With one eye on Sage, Marinus reports prelim PPD data
MoWuXi AppTec starts a global wave of expansion, jumping off in San Diego following $1B Hong Kong IPO raise
MoNasdaq celebrates record biotech IPO success in 2018. But can the party on Wall Street rumba on?
MoAstraZeneca, Cancer Research UK set up genomics hub to fight uphill battle against cancer
Mo0-for-2: Another faded drug star in Axovant's much-hyped pipeline falls, tarnishing Ramaswamy's deal-making rep
MoFDA slaps partial hold on MacroGenics for bispecific cancer trials as liver tox spurs safety fears
MoGilead locks in Daniel O'Day as CEO, tapping the Roche vet to rejuvenate growth
MoWith fresh company building lessons from Ablynx, Edwin Moses is ready to try it again as chair of neoantigen biotech Achilles
FrSanofi will eliminate 670 jobs in France; Moderna gets FDA orphan status for preclinical asset
FrDelay brings success for Roche as it finally wins FDA nod for Tecentriq regimen in frontline lung cancer
FrBristol-Myers vet Caroline Loew heads up Glympse Bio; Kaleido nabs GSK's CMO Katharine Knobil
FrFDA will allow observational studies as part of a push for real world evidence, new framework says
FrAccused of milking the CMS with co-pay kickbacks, J&J's Actelion settles case for $310M
FrAstraZeneca's prized Imfinzi/tremelimumab combo fails again - this time in head and neck cancer